Unknown

Dataset Information

0

Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.


ABSTRACT:

Background

Angiotensin-converting enzyme 2 is the receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses for entry into lung cells. Because ACE-2 may be modulated by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEIs and ARBs are at higher risk of coronavirus disease 2019 (COVID-19) pneumonia.

Aim

This study sought to analyze the association of COVID-19 pneumonia with previous treatment with ACEIs and ARBs.

Materials and methods

We retrospectively reviewed 684 consecutive patients hospitalized for suspected COVID-19 pneumonia and tested by polymerase chain reaction assay. Patients were split into two groups, according to whether (group 1, n = 484) or not (group 2, n = 250) COVID-19 was confirmed. Multivariable adjusted comparisons included a propensity score analysis.

Results

The mean age was 63.6 ± 18.7 years, and 302 patients (44%) were female. Hypertension was present in 42.6% and 38.4% of patients in groups 1 and 2, respectively (P = 0.28). Treatment with ARBs was more frequent in group 1 than group 2 (20.7% vs. 12.0%, respectively; odds ratio [OR] 1.92, 95% confidence interval [CI] 1.23-2.98; P = 0.004). No difference was found for treatment with ACEIs (12.7% vs. 15.7%, respectively; OR 0.81, 95% CI 0.52-1.26; P = 0.35). Propensity score-matched multivariable logistic regression confirmed a significant association between COVID-19 and previous treatment with ARBs (adjusted OR 2.36, 95% CI 1.38-4.04; P = 0.002). Significant interaction between ARBs and ACEIs for the risk of COVID-19 was observed in patients aged > 60 years, women, and hypertensive patients.

Conclusions

This study suggests that ACEIs and ARBs are not similarly associated with COVID-19. In this retrospective series, patients with COVID-19 pneumonia more frequently had previous treatment with ARBs compared with patients without COVID-19.

SUBMITTER: Georges JL 

PROVIDER: S-EPMC7751849 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.

Georges Jean-Louis JL   Gilles Floriane F   Cochet Hélène H   Bertrand Alisson A   De Tournemire Marie M   Monguillon Victorien V   Pasqualini Maeva M   Prevot Alix A   Roger Guillaume G   Saba Joseph J   Soltani Joséphine J   Koukabi-Fradelizi Mehrsa M   Beressi Jean-Paul JP   Laureana Cécile C   Prost Jean-François JF   Livarek Bernard B  

PloS one 20201221 12


<h4>Background</h4>Angiotensin-converting enzyme 2 is the receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses for entry into lung cells. Because ACE-2 may be modulated by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEIs and ARBs are at higher risk of coronavirus disease 2019 (COVID-19) pneumonia.<h4>Aim</h4>This study sought to analyze the association of COVID-19 pneumonia w  ...[more]

Similar Datasets

| S-EPMC9075226 | biostudies-literature
| S-EPMC7129862 | biostudies-literature
| S-EPMC8120409 | biostudies-literature
| S-EPMC6806420 | biostudies-literature
| S-EPMC8232748 | biostudies-literature
| S-EPMC3394697 | biostudies-literature
| S-EPMC4998053 | biostudies-literature
| S-EPMC4872747 | biostudies-literature
| S-EPMC7982393 | biostudies-literature
| S-EPMC7478439 | biostudies-literature